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Diabetes Treatment and
Cardiovascular Safety
ZACHARY T. BLOOMGARDEN, MD
T
his is the third of a series of articles
based on presentations at the Amer-
ican Diabetes Association (ADA)
70th Scientiﬁc Sessions, held 25–29
June2010inOrlando,Florida,pertaining
to the need for large-scale cardiovascular
(CV) safety requirements for the treat-
ment of diabetes. The term “contrarian”
is deﬁn e di nv a r i o u sw a y sa s“ap e r s o n
who takes an opposing view,” as “one
who rejects the majority opinion” (1), or
as “an investor who goes against current
market trends” (2). What might be char-
acterized as a “contrarian” debate on
diabetes discussed the new requirement
for large-scale CV safety studies on all
newglucose-loweringmedications.There
was also a discussion of an increasingly
recognized issue, potential inaccuracies
of capillary glucose test meters, and of
point-of-care A1C testing technologies.
CV SAFETY REQUIREMENTS
FOR NEW DIABETES
TREATMENTS—At the symposium,
Steven Nissen (Cleveland Clinic, Cleve-
land, OH) addressed the question of
whether diabetes drugs should have a
higher bar for CV safety than other drugs.
H eb e g a nw i t ha na c k n o w l e d g m e n to f
relationships with multiple pharmaceuti-
cal companies, although stating that all
income from such went to “charity.” He
then complained about the “ridiculous
t i t l ef o rad e b a t e , ” to suggest that the out-
come (presumably his) would be a fore-
gone conclusion. He stated that “all drugs
must be required to show a health out-
comes beneﬁt,” and that “diabetes drugs
are being held to [a] standard that is nei-
ther greater nor less than other ﬁelds.” He
acknowledged microvascular beneﬁts of
reduction in glycemia but stated that
“some ofthe drugsthatlower bloodsugar
actuallyincreasetheriskofmacrovascular
complications” and suggested this to
override microvascular disease, as “CVD
is the cause of death in most diabetic pa-
tients.” Furthermore, he questioned the
use of biomarkers as “surrogate for real
outcomesdata”andtermedthebloodglu-
cose concentration as simply a “bio-
marker.”“ Blood glucose measurements,”
he suggested, “are just the latest failure to
gain widespread attention (even though
this surrogate failed long ago).” This was
certainlyawaytodrawaudienceattention
at the ADA meeting!
Nissen reviewed the ﬁndings of the
University Group Diabetes Program and
the controversy that ensued over its
ﬁnding of increased all-cause and CV
mortality with tolbutamide (3). He
strongly implied intellectual dishonesty
o nt h ep a r to fs o m eo ft h o s ew h oc r i t i -
cized the study, citing a statement by
Theodore Schwartz and Curtis Meinert,
“Academicians, paid in cash or in grant
awards, were hired as consultants by the
Upjohn Company...writing highly criti-
cal assessments...challenging the hon-
esty of the University Group Diabetes
Program investigators” (4). Perhaps, he
implied, one might similarly attribute
base motives to those currently criticizing
claims of adverse CV effects of diabetes
treatments. An effect of sulfonylureas
was observed on ischemic precondition-
ing (5), offering a mechanism by which
tolbutamide might indeed have caused
adverse outcome. As a more recent case,
Nissen described studies of muraglitazar,
which lowers A1C and triglyceride and
raises HDL cholesterol levels, leading to
the argument that there was “lack of bi-
ologic plausibility for CV risk,” with
the agent leading a U.S. Food and Drug
Administration (FDA) advisory panel to
recommend approval. However, Nissen
reported increased mortality and major
CV event rates shortly after the panel’s
meeting,withtrendstoincreaseinall-cause
mortality and in congestive heart failure
(CHF) and increase signiﬁcantly in some
commonly used composite CV end points
(6), leading the FDA to request additional
CV safety data. Thus, Nissen concluded
that “a risky agent came close to approval
becausethesurrogateendpointsofglucose
and lipids did not predict CV outcomes.”
Next, Nissen discussed rosiglitazone,
pointing out that it is associated with an
increase in LDL cholesterol, particularly
among individuals with lower baseline
levels, as well as weight gain. In the Di-
abetesREductionAssessmentwithramipril
and rosiglitazone Medication (DREAM)
trial, he stated that there was a trend to a
37% increase in the composite end point
ofmyocardialinfarction,stroke,CVdeath,
CHF, new angina, and revascularization
(7, 8). [Only the increase in CHF was sta-
tistically signiﬁcant.] He noted that many
small studies were performed with rosigli-
tazone, with a total of 14,237 patients en-
rolled in 42 randomized trials completed
by 2007, although he characterized the
Rosiglitazone Evaluated for Cardiovascu-
lar Outcomes in Oral agent combination
theRapy for type 2 Diabetes (RECORD)
trial (9) as “hopelessly underpowered,”
so that meta-analysis was the only ap-
proach feasible in determining whether
there was “a safety signal.” He reported
suchameta-analysis,ﬁndingrosiglitazone
to be associated with a signiﬁcant 43% in-
creaseinmyocardialinfarction(10).[Fora
review of questions pertaining to this
meta-analysis, see Bloomgarden (11).] In
contrast, he termed the PROspective pio-
glitAzone Clinical Trial In macroVascular
Events (PROACTIVE) trial (12) “a large,
reasonably well-powered CV outcome
trial” showing a trend to improvement in
the primary end point and a signiﬁcant
reduction in the secondary end point of
death, myocardial infarction, and stroke,
albeit with signiﬁcantly increased rates of
CHF hospitalization. Nissen himself per-
formed ameta-analysis that supportedthe
PROACTIVE ﬁnding of reduction in these
outcomes (13), and he commented that
“pioglitazone appears to have a more fa-
vorable effect on lipids, particularly tri-
glycerides.” What of the Action to Control
CardiovascularRiskinDiabetes(ACCORD)
trial (14)? There was signiﬁcant and sus-
tained glycemic separation between the
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but a signiﬁcant increase in total and CV
mortality, although with signiﬁcant reduc-
tion in nonfatal myocardial infarction. “A
regimen in which more patients received
repaglinide, rosiglitazone, insulin and/or
an a-glucosidase inhibitor,” he concluded,
“showed increased mortality risk.”
Why, Nissen asked, are there “no
well-designed, adequately powered com-
parative effectiveness trials evaluating
macrovascular outcomes for diabetes
drugs,” although oral hypoglycemic
agents have been available for more than
50 years? He reviewed a comparative ef-
fectiveness and safety study for glucose-
lowering drugs (15), suggesting that the
levels of evidence that diabetes drugs re-
duce all-cause mortality, CVD mortality,
nonfatal myocardial infarction or stroke,
peripheral vascular disease, or even mi-
crovascular outcomes are “low to very
low!” [This study, however, speciﬁcally
excluded the UK Prospective Diabetes
Studyfrompartsofitsanalysis,andasub-
sequent analysis from the same group did
report signiﬁcant reduction in CV end
points with metformin (16).] Nissen
wentontoclaimthatneithermeta-analyses
nor what he termed “post hoc data dredg-
ing of randomized trials not designed to
determine the beneﬁts or risks of speciﬁc
therapies”willbeusefulindeterminingthe
cause of the excess mortality in ACCORD
and stated further that “no amount of
torturing of the data will enable risk as-
sessment when speciﬁc drugs are not ran-
domized,” although such a statement fails
to recognize that there is progressive de-
terioration in glycemic control in type 2
diabetes, so that treatment must be aug-
mented over time to maintain stable gly-
cemic control. However, Nissen termed
this a “knowledge gap” based on “current
regulatory policy that emphasizes the im-
portance of glucose lowering, not health
outcomes,asatherapeuticgoal,”whichhe
proposed to represent “glucocentricity,”
an “irrational belief that lowering blood
glucose using virtually any pharmacologic
means will produce a reliable reduction
in adverse outcomes.” He acknowledged
that there is “the need to bring new diabe-
tes agents to patients” but suggested that
robust outcome data are absolutely neces-
saryandcommentedfavorablyonthenew
FDA recommendation that preapproval
clinical trials must rule out a .1.8-fold
increase in hazards ratio (HR), with sub-
sequent outcomes trials considered “sufﬁ-
cient to rule out a HR .1.3” (17). Nissen
acknowledgedthatthelatteroutcometrials
would typically require 5–7 years. Using
such an approach, Nissen showed power
calculations for populations with 2% and
3% annual combined death, myocardial
infarction,andstroke event rates, withap-
proximately 5,000 patient-years of obser-
vation required to exclude a HR.1.8. [It
should be noted that “rule out” is deﬁned
strongly, as requiring that the 95% conﬁ-
dence limits not include the HR in ques-
tion, even if the actual HR itself is ,1.0.]
Furthermore, the population estimates of
Nissen’s calculation are predicated on an-
nual event rates $2.0%. This represents a
very different population from that usu-
ally enrolled in diabetes trials, with ex-
pected event rates at ;0.5% (18), for
which .20,000 patient-years of observa-
tion might be required for exclusion of a
1.8-foldincreaseinriskand.100,000for
exclusion of a 1.3-fold increase. Nissen
termed the requirement for such studies
as positive, and opined that patients at
higher CV risk must be included in the
testing of new diabetes agents, suggesting
thatitwouldonly“modestlyslowdevelop-
ment programs...delaying introduction
of new diabetes medications by 6–12
months.”
David Orloff (Medpace, Cincinnati,
OH) was the director of metabolic and
endocrine drugs at the FDA from 2000 to
2005 and is now employed by a clinical
research organization contracting with
the pharmaceutical industry. He began
by observing that he directs all income
from his consultation with the pharma-
ceutical industry to his organization. He
reviewed the rationale for the new FDA
guidanceandarguedthatonemusthavea
more rational notion of risk management
in diabetes and must take into account
what he termed “black swans.” He then
discussed the protean nature of diabetes,
in a sense taking and expanding on
Nissen’sn o t i o no f“glucocentricity” be-
fore discussing diabetes drug develop-
ment from a patient’sp e r s p e c t i v e .H e
concluded by reminding the audience
that the FDA must play roles not only
in regulation but also in encouraging in-
novation.
“The question of the day,” he said, is
whether all new diabetes drugs should be
required to demonstrate CV safety. The
FDA decision is in the afﬁrmative, “so
it’s not hypothetical.” Of course, he said,
one must accept the notion that having
more information is better and “that safe
is better than sorry.” However, he said
that the need did not consider the CV
safety proﬁles of all existing agents as
germane to the evaluation of all possible
new drugs, unless one thought that low-
ering glucose itself represented a CV risk.
If that were the case, then to be considered
a safe treatment, an approach would re-
quire an additional factor that offset the
putative adverse effect of glucose lowering.
There is not, he stated, any evidence that
glucose lowering is itself atherogenic, so
this position is not tenable.
Certainly, he agreed with the notion
of regulation of industry, and he sug-
gested that the FDA has played an impor-
tant role in development of high-quality
pharmacologic treatments. Although
“regulators and industry will not always
see eye to eye” and the regulators must
make the ﬁnal call, the FDA must be al-
lowed discretion, he said, to balance the
desire for a “level playing ﬁeld” with the
needforcase-by-casedecisions.Withthat
understanding, should a uniform ap-
proach be applied to the development
plan of all diabetes treatment agents?
The guidance requires demonstration
that a drug not be associated with the in-
creases in CV risk outlined by Nissen,
which indeed might require 4–6,000
treatment years of follow-up of high-CV
risk patients. The $2% annual event rate
supposition is, however, based on the no-
tionofdiabetesasaCVriskequivalent.As
CV risks decline in diabetic patients [see
discussion in Bloomgarden (19)], Orloff
suggested that ever largerand largerstudies
willberequiredforthe95%HRconﬁdence
intervals not to include a 1.8- and then
a 1.3-fold increase in risk as described
above. What will be the burden of demon-
strating “beyond a reasonable doubt” that
risk is not increased?
Orloff emphasized that the FDA
guidance does not require demonstration
of a reduction in CV risk. Certainly, CVD
isahugeissuefordiabeticandprediabetic
patients, and reduction in atherosclerosis
certainly is desirable, but such a study
would only demonstrate beneﬁt, he sug-
gested, if a diabetes agent led to reduction
in risk similar to that of statins. A further
issue, he said, is the paucity of compar-
isons of CV risk among drugs. [It is
noteworthy that there is evidence that
the thiazolidinediones available prior to
2001 may, similarly to metformin, be
associated with lower postmyocardial in-
farction mortality than other glucose-
lowering drugs (20).] Drug safety is not
an incorrect goal, he said, “but [to require
that] all ...new diabetes drugs should be
taken through the same battery of tests,”
becomesahugelyexpensiveundertaking.
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BloomgardenRisk management may be considered
the reduction in adverse events and
maximization of opportunities. From the
timeofdrugdiscoverythroughthelifetime
of a drug, one must make evidence-based
judgment regarding beneﬁts, and one
must do so “with a prepared mind,” aware
of all potential adverse effects. Orloff
stressed the need to follow evidence,
which he contrasted with “signals,” which
by deﬁnition do not represent statistically
signiﬁcant risks. This is particularly im-
portant if one is to consider the need for
rational expenditure of resources in the
development of new agents. The question
for a new drug that is unlikely to show
adverse CV effects then is whether the re-
mote possibility of such an effect should
be allowed to constitute the single most
important aspect of the evaluation of that
agent, requiring its developers to under-
take an immensely complex and expen-
sive trial.
Orloff discussed the notion of black
swans, popularized by the recent book by
Nassim Nicholas Taleb (21), suggesting
such a phenomenon to be an important
aspect of sudden changes in the global
economy. Juvenal, who had written ap-
proximately in the 1st century B.C.,
coined the expression, and it became for
centuries a standard simile in referring to
impossibilities. Actual black swans then
were discovered in Australia, seeming to
render the ﬁgure of speech meaningless!
“Black swans,” however, remain rare
in the universe of swans. Orloff asked,
then, whether those of us who have la-
bored under the misconception (or
hope) that glycemic control improves
CV outcome and those who have felt
comfortable that diabetes treatment is
s a f e ,o ra tl e a s tn e u t r a li nt e r m so fC V
effect, should now be expected to take
this opposite view. If there is a diabetes
drug that exacerbates CV risk, must one
ask the question: given the “absolute cer-
tainty that not all diabetes drugs will be
atherosclerosis-safe, does it follow that all
diabetes drugs [might] be atherosclerosis-
promoting?That’stheblackswan,”hesaid.
Orloff said that diabetes certainly is
protean in its effects, and he acknowl-
edged the pitfalls in being “glucocentric,”
but it is difﬁcult to argue against glycemic
control being life-saving. Yes, he said, di-
abetes is certainly far more than a disease
of insulin action and altered glucose, and
it is a disease of lipids, liver, brain, gut,
andmanyother organsandmetabolicsys-
tems. We do have great deal to be done
in developing appropriate treatments.
Diabetes drugs then should not be viewed
as simply glucose-lowering agents, but
“perhaps we need to approach it from a
different angle,” that a diabetes drug “is
simply a drug for a patient with diabetes.”
In that sense, drugs for CVD, developed
separately from drugs for dysglycemia,
might be a huge step forward. “It is not
clear,” he explained, that adverse CV ef-
fects must “become the prime safety
concern.” We need to address all compli-
cations and endeavor to ameliorate them
all,and we should beaware ofanyadverse
effects, “but obligatory focus on any single
aspect” may not be proper “rational prior-
itization of resources.”
From the patient’s perspective, Orloff
suggested that one must know how an
agent will be helpful in improving out-
come and how it will compare with other
options, including doing nothing. It is best
to have multiple choices, in case a given
agent has particular adverse effects for a
given person. What if a given individual
does not “ﬁt” into the proﬁle of the clinical
trialdatabase?Ifapatientistoldthatagiven
agent is unlikelyto increase CV risk,will he
be comforted? Ifa patient has a 1% CV risk
over the present year, would a possible in-
creasetonomorethan1.5%becomforting?
Innovation“isthebaneofexistenceof
regulators, doctors, patients, and indus-
try,” and Orloff suggested that “perhaps
our most nerve-wracking” task is know-
ing what is safe. However, developing
new therapies is a crucial responsibility
of the regulatory agency, as Orloff stated,
not just the goal of industry, “and in the
end, whether intentional or not, the
agency’s stances can either quash or stim-
ulate.” We must then make sure that “the
costs and risks of development” do not
become prohibitive, which would drive
pharmaceutical companies away from the
development of new approaches to diabe-
tes and would certainly cause further in-
creases in costs of those medications that
do come to market. “We should direct our
energies and our spending as appropriate,”
he concluded, “from case to case.” This
argument seems to carry weight, and it
will be fascinating to see whether the FDA
responds to voices such as Orloff’s argu-
ment that extensive CV safety studies
mustnotbecomeindispensableindiabetes
drug development.
POINT-OF-CARE DEVICES
FOR MANAGEMENT OF
DIABETES—Continuing an annual se-
ries of combined American Diabetes As-
sociation(ADA)–AmericanAssociationof
Clinical Chemists Symposia, a pair of
talks were entitled “Point-of-Care (POC)
Devices for Glucose and HbA1c–Are
They Up to the Task?” Mitchell G. Scott
(Washington University School of Medi-
cine, St. Louis, MO) discussed the need
for greater accuracy with glucose meters,
reviewing common interfering substances,
comparing different criteria for acceptable
performance of meters, and discussing
whether different outcomes of tight gly-
cemic control studies might in part be the
result of errors from use of such devices in
estimating glucose levels. Currently avail-
able meters are smaller than those in the
past, and more than 30 different devices
are now available. Over the past few years
“no wipe” strips, smaller sample sizes,
faster analytic responses, and data storage
and capture have become standard, and
alternate site testing has become available
but with a time lag issue (22). Many hos-
pital systems use measures to “lockout”
results if quality standards are not met.
POC glucose testing has become a huge
($6 billion/year) market, comprising
nearly one third of laboratory-testing
costs.
Interferences are not uncommon.
Because the values are standardized for
plasma glucose on almost all meters
currently in use, anemia increases and
polycythemia decreases glucose values
(23,24). Reducing agents, such as ascor-
bic acid at levels seen with commonly
taken doses (25) and acetaminophen
withsomemethodologies(26),willlower
measured glucose levels, although some
new meters can correct for hematocrit
and reducing agents (27). Glucose
dehydrogenase methods are affected by
maltose-containing substances, such as
intravenous immunoglobulin, or by iso-
dextrin, which is found in peritoneal di-
alysis ﬂuids (28); since the mid-1990s,
Scott noted that therehave been 13 docu-
mented deaths from such interference.
User errors are another important issue,
as strip manipulation readily alters glu-
cose readings with some meters.
In critical care settings, most centers
have adopted protocols to maintain the
blood glucose below 130 mg/dL, requir-
ing frequent glucose testing and insulin
infusion rate adjustment. This has mark-
edly increased the use of strips in hospi-
tals, with Scott noting that the annual
number of test strips used at his institu-
tion increased from approximately
250,000 to 550,000 from 2000 to 2009,
with nearly half of strips used in criti-
cal care units. Tight glycemic control in
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mortality or morbidity in a meta-analysis
of 27 studies, while being associated with
increased likelihood of hypoglycemia
(29). In particular, the Normoglycemia
in Intensive Care Evaluation and Survival
Using Glucose Algorithm Regulation
(NICE-SUGAR) trial showed decreased
survival with tight glycemic control in as-
sociation with increased hypoglycemia
(30). How can one reconcile the better
outcome in the original Van Den Berghe
studies (31,32) with these reports? Scott
pointed out that the original studies used
arterial blood glucose measurement with
blood gas instrument methods, giving
highly precise values, whereas many of
the studies showing null or negative effect
seem to have used glucose meters. Unfor-
tunately, few of these studies report the
actual glucose measurement methodolo-
gies used, particularly when carried out
at more than one center. Anemia is com-
monly found in critical care patients, po-
tentiallycausingoverestimationofglucose
levels. Sampling site is of great impor-
tance. Scott reviewed a study of 20 CV
surgery patients comparing arterial, ve-
nous, and capillary blood specimens,
showing that, with use of strip methods,
arterial samples led to an overestimate of
15 mg/dL, with even greater inaccuracy
using venous blood samples (33). Scott
and associates have suggested that it is
likely that meter glucose measurements
may lead to hypoglycemia (34) and that
such measurements may not be sufﬁ-
ciently accurate for in-hospital use. Like-
wise, these measurements should not be
used in diagnosis of diabetes, which leads
to the question of whether we may incor-
rectly advise outpatient treatments when
we rely on self-monitoring using such ap-
proaches.(Onealsomightaskwhethercal-
ibration of continuous glucose monitoring
by capillary glucose measurements risks
perpetuationofinaccuratemeasurements.)
The current allowable error for labo-
ratory oratory glucose measurements is
10% or 6 mg/dL for “main laboratory” or
arterial blood glucose methods, a level
considered sufﬁciently precise to be
used in the diagnosis of diabetes. For me-
ters, the ADA standard requires that total
analytic error be ,5%, but Scott pointed
out that “there’s not a meter around that
will do this.” Other testing programs
have suggested that the minimal stan-
dard be the greater of 20% or 12 mg/dL;
or 20% if .75 mg/dL, 15 mg/dL if ,75
mg/dL, for 95% of values; or the stan-
dard suggested by the FDA, 20% for
glucose $ 1 0 0m g / d La n d1 2m g / d L
for ,100, again for 95% of values (35).
The Clarke Error Grid, a commonly used
methodology for determining meter accu-
racy, may no longer be suitable for assur-
ing that meters are sufﬁciently precise.
By use of the Hemo-Cue test as a
reference method, in a 1973 study of
capillary blood samples from pregnant
women measured by a registered nurse,
highvariabilitywasshown(36).Inacom-
parison study of ﬁve meters with sample
testing by a medical technician, using 93
individuals,with12samplesobtainedper
patient, 2 with each meter, the coefﬁcient
of variability (c.v., deﬁned as the SD 3
100/mean) ranged from 6.3 to 11.3%,
with the differences between meters vary-
ing with glucose concentration and meter
pairs, showing a 1–32% bias (37). An-
other study, comparing four meters,
found a c.v. of 1.4–8.7% in tests on 54
patients with nine operators and six rep-
licates (38). The greatest inaccuracy, as
reﬂected by c.v., was seen at low glucose
levels. Scott observed that the Clarke
Error Grid allowed what seemed to be
unacceptable degrees of error in this
study. Finally, a study comparing blood
gasanalyzerwith mainlaboratory glucose
showed only 1% of values having .20%
error, suggesting that this approach is
usually quite accurate, whereas in the
same study, particularly with capillary
sampling, meters often overestimated ac-
tual blood glucose (39).
In a 2009 survey by the College of
American Pathologists, with four of the
most commonly used meters, the c.v.
averaged 5.3%, 6.0%, 4.7%, and 4.8%
but varied from laboratory to laboratory.
At Washington University School of
Medicine, ;200 meters are used by
.2,000 operators, testing ;1,400 values
daily; the c.v. for low and high glucose
values were 8.8% and 5.9%, respectively.
Scott pointed out that few repeat glucose
tests are done, perhaps because they are
not billable, but that of those done re-
cently, the mean absolute difference was
84 mg/dL, leading him to ask, “How
many [inaccurate glucose values] are not
being picked up that way?” New meters
may be able to correct for anemia and re-
ducing substances and may have 2–3%
imprecision and relatively small bias.
Scott suggested that we require that
values within 10% of actual glucose and
within 10 mg/dL for glucose levels ,100
mg/dL and argued that such an approach
seems possible. A new error grid has been
proposed, requiring that 95% of values be
within 10% or 10 mg/dL and that 99% be
within15%or12mg/dL,sothat,1%will
exceed this level of abnormality (40,41).
There currently is no direct comparison
of meter versus blood gas analyzer in out-
come, but Scott reviewed an analysis that
usesaMonteCarlomodelingmethod,sug-
gesting that simulation of the clinical
effects of measurement error might be a
useful approach to determining appropri-
ate standards for these methodologies
(and,presumably,for eventualuse ofcon-
tinuous blood glucose-monitoring meth-
ods) (42).
Richard Hellman (Kansas City, KS)
reviewed some of the same information
on issues with use of POC devices for
measuring blood glucose. A New York
Times article brought to public attention
the tremendous variability of out-of-
hospital glucose measurements withavail-
able meters (43) and was followed by an
FDA/Center for Devices and Radiological
Health (CDRH) Public Meeting on the
topic of Blood Glucose Meters, held on
16–17 March 2010 at the Hilton Wash-
ingtonDCNorth/GaithersburgHotel,ex-
amining whether there is need to change
meter standards, with the consensus that
improvement is needed.
In addition to the issues raised by
Scott with in-hospital measurements,
Hellman noted that hypotension leads
glucose oxidase-based test strip methods
to overestimate glucose levels, whereas
glucose dehydrogenase methods may be
either increased or decreased, with nearly
two thirds of values showing .20% var-
iance (28,44). Even small changes in me-
ter precision or bias have the potential to
cause adverse outcome, and Hellman ob-
served that “outliers are dangerous,” mis-
leading both the patient and the provider
and potentially causing harm, whether
fromhighorlowestimates.Thedilemma,
however, is that “we need the real-time
information that the meters provide.” If
maltose-containingsubstancescausefalse
elevation with glucose dehydrogenase,
Hellman asked whether there is an effect
of other dietary sugars? Might fruits, veg-
etables, herbs, and other dietary products
containing xylose and galactose cause in-
terference? The effects of anemia and
polycythemia on meter accuracy are im-
portant as well. Many hospitals fail to im-
plement comprehensive quality control
testing for POC meters, and even more
important, personnel who perform the
testingrarelyaretaughtthecharacteristics
of the meters in accuracy, precision, and
sensitivity to interference.
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with glucose tests strips shows lot-to-lot
variation, with Hellman also wondering
whether such variability might be related
to the ﬁndings of adverse outcome of
intensive glycemic control in NICE-
SUGAR (45). Hypoglycemia is not, of
course, the only issue for hospitalized di-
abeticpatients;HellmanreviewedaMedi-
care identiﬁcation of “things that should
never happen but did,” with 14,929 epi-
sodes of diabetic ketoacidosis and hy-
perosmolar coma developing among
hospitalized patients in 2007. What he
considered “the real problem in the hospi-
tal” was “untreated hyperglycemia both in
the ICU and on the ﬂoors,” so accurate
glucose measurement is crucial. Out-of-
hospital ketoacidosis also may occur in in-
dividuals having incorrectly low glucose
readings(46).Manyofthemetershavebet-
terperformancecharacteristicsatonerange
than another, so that meters having falsely
high levels in the low range will result in
disproportionate risk for hypoglycemia.
Another issue, Hellman raised, is the
consequenceofnotknowingwhichmeter
was being used. This has particularly
become problematic when the choice of
meter is dictated by the patient’sp h a r -
macy beneﬁtp l a n .“The irony,” Hellman
emphasized, “is that the insurance [bene-
ﬁt provider] could take our patients and
give them that [less accurate] meter be-
cause it’s cheaper. We would like better
meters, but they may cost more.” Payers
and pharmacy beneﬁt managers should
not be permitted to arbitrarily change pa-
tients’ POC meters without input from
the patient and provider, and any pro-
posed new meter should have accuracy,
precision, and ease of learning at least
equivalent to the previous meter.
There are issues when the measure-
ment is not properly performed by the
patient. Failure to wash can cause both
high and low glucose values. Failure to
dry the hands causes hemodilution, and
sluggish blood ﬂow from hemoconcen-
tration,vasospasm,orhyperviscositymay
lead to inadequate sample size causing
falsely low results. Most published data
on accuracy and precision involve studies
performed by highly trained technicians
with properlystored new strips,with well
cared for meters. Such results may not be
foundinusualpatientcare, where thec.v.
is nearly 50% greater than that in the
inpatient setting (47). In addition, there
arelot-to-lotvariations,withHellmannot-
ing that more than half of the instruments
studied show more hematocrit-induced
error in glucose levels than acknowledged
in the manufacturers’ documentation.
Storage for 30 min at low or high temper-
atures also lead to error, and we lack good
s tudi eso nt heu sef ull i f eo fmete rs.W i thou t
speciﬁc efforts to maintain patient proﬁ-
ciency, such as the use of mailed unknown
samples from a central agency, inaccurate
testing may occur over time even after ap-
propriate patient education. Furthermore,
many patients do not have effective educa-
tion in self-monitoring, with older patients
given written materials rather than in-per-
son education being particularly likely not
to test correctly.
We then need to ﬁnd a balance be-
tween convenience, cost, size, and
speed on the one hand and accuracy on
the other hand. In critical care settings,
Hellman stated, “accuracy and precision
are life-saving,” and must not be affected
by change in hematocrit, hypotension,
hypoxia, or interfering substances, so
that it may not be appropriate to care for
patients in these settings with instruments
other than blood gas multichannel ana-
lyzers. Hellman suggested that for glucose
levels $75 mg/dL, 95% of values should
bewithin10%,99%ofvalueswithin15%,
and 99.9% within 20% of actual, and for
glucose levels ,75, the respective accu-
racy criteria should be 10, 15, and 20
mg/dL. Strip lots, Hellman said, should
be tested systematically by a FDA-
approved entity for accuracy, and the
results should be publically available.
Manufacturers have a responsibility to
provide effective educational materials
on POC meters. Glucose meters should
contain software so that date- and time-
stamped glucose levels can be securely
downloaded using an industry-standard
interface to be available for patients and
providers without charge. Most impor-
tantly, Hellman concluded that “health
care providers should notusePOC meters
uncritically, especially when the clinical
setting makes these values suspect.”
TheremaybesimilarissueswithPOC
A1C testing. At the National Glycohemo-
globin Standardization Program (NGSP)
Clinical Advisory Committee meeting at
the ADA, David Sacks (Boston, MA)
discussed this matter, noting that POC
testing may incorporate immunoassay
or boronate afﬁnity chromatography,
the latter infrequently used in clinical
laboratories. Between laboratory A1C, c.v.
values are typically ,3.5%, and within a
given laboratory, the c.v. may be ,1.0%.
The Clinical Laboratory Improvement
Amendments (CLIA) act of 1988 allows
waiver of “test systems [which] are sim-
ple...cleared by FDA for home use...
so simple and accurate as to render the
likelihood of erroneous results negligible,
orposenoreasonableriskofharm.”Based
on this waiver, six POC A1C devices have
beenNGSP-certiﬁed.Advantagesarethese
devices’ rapidity, convenience, and the
CLIA waiver, allowing testing to be per-
formed in the physicians’ ofﬁce. There is
evidence that immediate A1C feedback
improves outcome. Disadvantages are
greater expense and the lack of require-
ment for proﬁciency testing; thus, there
is very limited objective data regarding
performance in patient care and potential
lackofprecisioninthehandsofthosewho
use them. How accurate, Sacks asked,
should one expect the A1C measurement
to be? If a specimen has A1C 6.5%, with a
c.v. of 4%, the 2 SD range would be 5.98–
7.02, with 3%, 6.11–6.89, and with 2%,
6.24–6.76. Is it necessary then for the c.v.
tobe,2%for acceptable precision? Sacks
argued that if A1C is used for diagnosis
a n de v e ni fi ti su s e df o rm a n a g e m e n t ,
the between-laboratory c.v. should be
low. Sacks reviewed a study of eight com-
mercialPOCA1Cdevices(48).Twoofthe
manufacturers withdrew their devices af-
ter initial poor results, but only two of the
others had c.v. ,3%, and only one device
met current NGSP criteria with two differ-
ent lots. The bias of the devices ranged
from20.9%to10.4%.Notingthatapos-
itive 0.4% A1C bias would more than
double the number of individuals diag-
nosed with diabetes, Sacks reviewed cur-
rent ADA guidelines, which suggest that
POC devices not be used for the diagnosis
of diabetes. Of course, one must be con-
cerned about both positive and negative
biasesinuseofthesedevicesinclinicalcare.
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